Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
401
Recruiting Now
401
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT07334431 Phase 1, Phase 2
Recruiting
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Pati...
Condition
Gastric Adenocarcinoma
Enrollment
45 pts
Location
China
Sponsor
Henan Cancer Hospital
NCT06672575 Phase 1, Phase 2
Recruiting
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
Condition
Glioblastoma
Enrollment
45 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06081686 Phase 1, Phase 2
Recruiting
Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
Condition
Prostate Cancer
Enrollment
32 pts
Location
China
Sponsor
Sinotau Pharmaceutical Group
NCT04165070 Phase 1, Phase 2
Recruiting
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) ...
Condition
Carcinoma, Non-Small-Cell Lung
Enrollment
450 pts
Location
United States, Canada, Hungary
Sponsor
Merck Sharp & Dohme LLC
NCT07519772 Phase 1, Phase 2
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Condition
Lymphoma, Non-Hodgkin
Enrollment
280 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT07389239 Phase 1, Phase 2
Recruiting
A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Adva...
Condition
Ovarian Cancer
Enrollment
24 pts
Location
United States
Sponsor
University of Chicago
NCT06844422 Phase 1, Phase 2
Recruiting
Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enh...
Condition
Pancreatic Cancer
Enrollment
37 pts
Location
China
Sponsor
Shandong Cancer Hospital and I
NCT06828042 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Auto...
Condition
Systemic Lupus Erthematosus
Enrollment
9 pts
Location
China
Sponsor
Peking University Third Hospit
NCT07547553 Phase 1, Phase 2
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatm...
Condition
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Enrollment
30 pts
Location
China
Sponsor
Huahui Health
NCT04390737 Phase 1, Phase 2
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
Condition
FL Lymphoma
Enrollment
254 pts
Location
United States, China
Sponsor
Haihe Biopharma Co., Ltd.
NCT06814496 Phase 1, Phase 2
Recruiting
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Condition
Melanoma
Enrollment
30 pts
Location
United States
Sponsor
University of Arizona
NCT07399769 Phase 1, Phase 2
Recruiting
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
Condition
Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue)
Enrollment
20 pts
Location
China
Sponsor
Shenzhen University General Ho
NCT06638502 Phase 1, Phase 2
Recruiting
Safety of HRX215 in Patients After Minor and Major Liver Resection
Condition
Liver Resection
Enrollment
80 pts
Location
United States, France, Germany
Sponsor
HepaRegeniX GmbH
NCT07326488 Phase 1, Phase 2
Recruiting
A Study of MHB009C in Patients With Advanced Solid Tumors
Condition
Advanced Malignant Solid Tumor
Enrollment
200 pts
Location
China
Sponsor
Minghui Pharmaceutical (Hangzh
NCT05150691 Phase 1, Phase 2
Recruiting
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Condition
HER2-positive Advanced Solid Tumor
Enrollment
796 pts
Location
United States, Australia, China
Sponsor
DualityBio Inc.
NCT07554924 Phase 1, Phase 2
Recruiting
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spina...
Condition
Spinal Muscular Atrophy 1
Enrollment
11 pts
Location
China
Sponsor
Lanyue Biotech (Hangzhou) Co.,
NCT06909110 Phase 1, Phase 2
Recruiting
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus...
Condition
Adenovirus
Enrollment
25 pts
Location
United States
Sponsor
Jessie L. Alexander
NCT05626920 Phase 1, Phase 2
Recruiting
Disulfiram for Treatment of Retinal Degeneration
Condition
Inherited Retinal Dystrophy Primarily Involving Sensory Retina
Enrollment
30 pts
Location
United States
Sponsor
University of Washington
NCT07172646 Phase 1, Phase 2
Recruiting
A Study of SRSD216 in Patients With Elevated Lipoprotein (a)
Condition
Hyperlipoproteinemia (a)
Enrollment
84 pts
Location
China
Sponsor
Sirius Therapeutics Co., Ltd.
NCT07043946 Phase 1, Phase 2
Recruiting
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
Condition
Immune Thrombocytopenia (ITP)
Enrollment
24 pts
Location
Bulgaria, Greece, Serbia
Sponsor
Climb Bio, Inc.
NCT05747261 Phase 1, Phase 2
Recruiting
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying th...
Condition
Spinal Muscular Atrophy (SMA)
Enrollment
40 pts
Location
Belarus, Russia
Sponsor
Biocad
NCT06878742 Phase 1, Phase 2
Recruiting
Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infa...
Condition
Infant, Premature, Diseases
Enrollment
30 pts
Location
Spain
Sponsor
Instituto de Investigación Hos
NCT06520488 Phase 1, Phase 2
Recruiting
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid ...
Condition
Advanced Solid Tumors
Enrollment
118 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co.,
NCT07363486 Phase 1, Phase 2
Recruiting
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resi...
Condition
Prostate Cancer
Enrollment
9 pts
Location
China
Sponsor
First Affiliated Hospital of F
NCT07559097 Phase 1, Phase 2
Recruiting
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathec...
Condition
Leptomeningeal Metastasis From Lung Cancer
Enrollment
14 pts
Location
China
Sponsor
Henan Cancer Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology